Advances in Colorectal Cancer Detection: Exploring the Role of Blood-Based Tests
Peter Buch, MD, FACG, AGAF, FACP
Aasma Shaukat, MD, MPH
Next-Generation Horizons in PNH Therapies
Vinod Pullarkat, MD
Managing PNH Patients: Addressing the Unmet Needs
Charles Turck, PharmD, BCPS, BCCCP
Brian Mulherin, MD
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
MOA: CDH6-Targeted Antibody-Drug Conjugates
Kathleen Moore, MD, MS
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
Joyce F. Liu, MD, MPH
CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian Cancer
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
Assessing Atirmociclib Plus Letrozole in HR+/HER2- Metastatic Breast Cancer
Pavani Chalasani, MD, MPH
Antonio Giordano, MD, PhD
Axatilimab for cGVHD: Assessing Organ-Specific Responses in AGAVE-201
Shernan Holtan, MD
Alicia Lieberman, MD, MS
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Michael Wang, MD
Advancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
David Feller-Kopman, MD
Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Evaluating Axatilimab in Chronic GVHD: How Prior Therapies Impact Outcomes
Hallie Blevins, PhD.
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.